A double blind Placebo Controlled randomised Trial of Adalimumab in the treatment of Hidradenitis Suppurativa

British Journal of Dermatology, 04/04/2011

A significant reduction was seen in Sartorius after 6 weeks and an almost significant reduction was seen after 12 weeks of active treatment when compared to the placebo–group. Significant reduction in Hidradenitis Suppurativa severity was gained after 6 weeks. No long–term curative effect was uniformly seen.

Author Commentary

In this pilot randomised clinical trial we present further evidence supporting the efficacy of TNF alpha blockage in hidradenitis suppurativa

Print Article Summary Cat 2 CME Report